Lysosomal Storage Diseases, Nervous System  >>  Replagal (agalsidase alfa)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Replagal (agalsidase alfa) / Samaritan Pharma, Takeda
NCT01218659 / 2010-022636-37: Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Completed
3
68
Japan, US, Europe, RoW
migalastat hydrochloride, AT1001, Migalastat, Galafold, agalsidase, agalsidase beta; Fabrazyme, agalsidase alfa; Replagal
Amicus Therapeutics
Fabry Disease
05/14
05/15

Download Options